Aptose Biosciences Inc (APTO) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aptose Biosciences Inc   (APTO)


Aptose Biosciences Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Aptose Biosciences Inc 's ROA in the first quarter of 2026?
Aptose Biosciences Inc recorded a cumulative net loss of $-28 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -81.69%.

However, within the Healthcare sector 895 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4573, from total ROA ranking in the fourth quarter of 2025 at 5297.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Total Assets Change 43.61 % 11.99 % 112.36 % 34.17 % 23.69 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -28 -25 -19 -21 -21
Return On Assets (TTM) -81.69 % -77.36 % -64.49 % -72.65 % -74.28 %
APTO's Total Ranking # 4573 # 5297 # 4666 # 4720 # 4763
Total Assets (TTM) in million 11 112 6 6 7
Seq. Total Assets Change -90.45 % 1670.73 % 13.41 % -25.12 % -92.55 %
Seq. Net Income Change - - - - -

APTO's 5 Years Annual ROA >> Back to APTO Management Effectiveness >> Compare APTO ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 139
Sector # 896
Overall # 4523

Return On Assets Statistics
High Average Low
-46.65 %
-141.52 %
-346.37 %
(Sep 30 2020)   (Dec 31 2025)



  News about Aptose Biosciences Inc Return on Assets ROA

Revamping AML Treatment Aptose Therapeutics Launches TUSCANY Phase 1/2 Study with Tuspetinib Triplet Therapy

In a groundbreaking development for the treatment of acute myeloid leukemia (AML), Aptose Therapeutics, a leader in oncology innovation, has announced the initiation of the TUSCANY Phase 1/2 study. This pioneering clinical trial aims to evaluate the efficacy and safety of a triplet therapy centered around Tuspetinib, a targeted therapy specifically designed for newly diagnosed AML patients. Understanding the Challenge of AMLAcute myeloid leukemia is a type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells. AML poses significant clinical challenges due to its complex biology and aggressive nature, leading to poor prognosis in many patients. Despite advances in treatment strategies, including chemotherapy and stem cell transplantation, there remains a substantial need for novel therapeutic options that can improve outcomes for patients diagnosed with this formidable disease.



Financial Statements
Aptose Biosciences Inc 's Assets $ 11 million APTO's Balance sheet
Aptose Biosciences Inc 's Income $ -8 million Quarterly APTO's Income Statement
APTO's Income by Division See APTO's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 11.99 % 4.74 % 6.44 % -17.24 % 80.64 %
Total Assets in million 112 100 96 90 109
Y / Y Net Income Change - - - - -
Net Income in million -25 -25 -51 -42 -65
Annual Return On Assets -22.68 % -25.36 % -53.49 % -46.5 % -60.14 %

APTO's 5 Years Annual ROA >> Back to APTO Management Effectiveness >> Compare APTO ROA to its Competitors



More Return On Assets Ratios
APTO's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
APTO's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for APTO's Competitors
Subscribers only: Roa for Aptose Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for APTO's Customers

You may also want to know
APTO's Roi APTO's Inventory Turnover Ratio APTO's Growth Rates APTO's Dividend Comparisons
APTO's Profitability Ratios APTO's Asset Turnover Ratio APTO's Dividend Growth
APTO's Roe APTO's Valuation Ratios APTO's Financial Strength Ratios APTO's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA

Date modified: 2026-06-23T17:39:04+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.